Form 4: Spyre Therapeutics Director Receives Stock Option Grant

Director Sandra Milligan was granted 8,026 stock options in Spyre Therapeutics, Inc. as part of standard equity compensation.

Summary

• Director Sandra Milligan received a grant of 8,026 stock options for Spyre Therapeutics, Inc. (SYRE) common stock.
• The options have an exercise price of $72.51 per share.
• The grant date for these options is May 27, 2026.
• The options are scheduled to vest on the earlier of May 27, 2027, or the date of the 2027 annual meeting of stockholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on the company's financial position.

Positives

• Aligns director interests with long-term shareholder value through equity-based compensation.

Negatives

• Results in potential future dilution for existing shareholders upon exercise of the options.

Risks

• Vesting is contingent upon the director's continuous service to the company.

Future Outlook

The options vest in one year, contingent on continued service, reflecting standard director retention and incentive practices.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are a standard corporate governance practice in the biotechnology sector to ensure board alignment with company performance.

Comparison to Industry Standards

• The grant of stock options to directors is consistent with standard compensation packages for mid-cap biotechnology firms.
• The one-year vesting period is typical for annual director equity awards.

Stakeholder Impact

• Minor potential dilution for shareholders upon future exercise of options.

Next Steps

• Vesting of options on May 27, 2027, or the 2027 annual meeting date.

Key Dates

Keywords

Spyre Therapeutics, SYRE, Form 4, Stock Options, Director Compensation, Insider Transaction